{"id":"anticov-220","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the spike protein, preventing the virus from entering host cells. This neutralization of the virus is thought to be the primary mechanism of action for AntiCov-220.","oneSentence":"AntiCov-220 is an antibody that targets the SARS-CoV-2 spike protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:29.933Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19"}]},"trialDetails":[{"nctId":"NCT05043324","phase":"PHASE4","title":"Prevention and Treatment of Patient Before, During, and After Covid-19 Infection","status":"COMPLETED","sponsor":"Nguyen Thi Trieu, MD","startDate":"2020-02-20","conditions":"Covid19","enrollment":82}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["1a","1b"],"phase":"marketed","status":"active","brandName":"AntiCov-220","genericName":"AntiCov-220","companyName":"Nguyen Thi Trieu, MD","companyId":"nguyen-thi-trieu-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AntiCov-220 is an antibody that targets the SARS-CoV-2 spike protein. Used for Prevention of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}